Screening for malignant melanoma: A cost-effectiveness analysis

摘要: Abstract Background: Skin cancer is the most common in United States. Increasing evidence suggests that screening for malignant melanoma effective, but its cost-effectiveness has not been determined. Objective: We attempted to determine effectiveness and costs of a visual screen diagnose high-risk persons. Methods: developed decision analysis comparing no skin with single by dermatologist. Clinical outcomes included melanoma, nonmelanoma cancer, or cancer. Life expectancy care were projected on basis clinical findings. Results: increased average discounted life from 15.0963 years 15.0975 years. Based prevalence however, this translates into an 0.9231 each person diagnosed melanoma. Using cost $30 per screen, total cancer–related cohort 1 million people $826 $861 screening, increase 1200 life. This results incremental ratio $29,170 year saved (YLS) screening. Sensitivity showed remained below $50,000/YLS if screened population was at least 0.0009, probability detected localized 94.8%, $57. Conclusion: patients likely be associated small reasonably cost-effective compared other strategies. (J Am Acad Dermatol 1999;41:738-45.)